Relapse/refractory myeloma patient: Potential treatment guidelines

Journal of Clinical Oncology

Volumn 27, Issue 34, 2009, Pages 5676-5677

  San Miguel, Jesús F ^a  

^a CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; PYRAZINE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL DECISION MAKING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYELOMA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; MULTIPLE MYELOMA; NOTE; RECURRENT DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; THALIDOMIDE;

EID: 73349122918     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.3683     Document Type: Editorial

References (6)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008
2. San-Miguel J, Harousseau JL, Joshua D, et al: Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 26:2761-2766, 2008
3. Richardson PG, Weller E, Jagannath S, et al: Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/ refractory multiple myeloma. J Clin Oncol 27:5713-5719, 2009
4. Richardson P, Jagannath S, Jakubowiak A, et al: Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): Encouraging response rates and tolerability with correlations of outcome and adverse cytogenetics in a phase II study. ASH Annual Meeting Abstracts 111:614a, 2008 (abstr 1742)
5. Reece DE, Rodriguez GP, Chen C, et al: A phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed/refractory multiple myeloma. J Clin Oncol 26:4777-4783, 2008
6. Knop S, Gerecke C, Liebisch P, et al: The efficacy and toxicity of the RAD regimen (Revlimid(R), Adriamycin(R), dexamethasone) in relapsed and refractory multiple myeloma: A phase I/II trial of "Deutsche Studiengruppe Multiples Myelom." ASH Annual Meeting Abstracts 110:797a, 2007 (abstr 2716)